Skip to main content
. Author manuscript; available in PMC: 2023 Nov 15.
Published in final edited form as: Clin Cancer Res. 2023 May 15;29(10):1969–1983. doi: 10.1158/1078-0432.CCR-22-2254

Figure 3. FST decreases bulk cell proliferation.

Figure 3.

A. Cell counts of HEY1, CaOV3 and OVSAHO cell lines treated for 72h with 0 ng/mL 10 ng/mL, 100 ng/mL, or 200 ng/mL FST. B. Cell counts of OVSAHO cells treated with indicated concentrations of FST, IgG and anti-FST neutralizing antibody. C. Cell viability assay of CaOV3 and OVSAHO cells treated with vehicle or 200ng/mL FST for 72h. D. Cell cycle analysis of OVSAHO and CaOV3 cells treated with 0 ng/mL or 200 ng/mL FST for 48h. E. HEY1 cells expressing the p27-venus and CDT1-mCherry FUCCI cell cycle reporter constructs were treated with or without 200 ng/mL FST and flow cytometry analysis was performed and the percentage of p27 and CDT1 double positive cells was graphed. F. Average fold change in cell counts of PT340 and PT412 (pooled results) CellTrace Violet sorted Bright (slowly dividing), and Dim (rapidly dividing) cell populations treated with vehicle or 200 ng FST. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.